Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   35419   clinical trials with a EudraCT protocol, of which   5814   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children 2 to 9 Years of Age

    Summary
    EudraCT number
    2018-001471-20
    Trial protocol
    Outside EU/EEA  
    Global end of trial date
    10 Oct 2017

    Results information
    Results version number
    v1(current)
    This version publication date
    29 Dec 2018
    First version publication date
    29 Dec 2018
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    MET35
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT03077438
    WHO universal trial number (UTN)
    U1111-1161-2625
    Sponsors
    Sponsor organisation name
    Sanofi Pasteur Inc.
    Sponsor organisation address
    1 Discovery Drive, Swiftwater, United States, 18370
    Public contact
    Trial Transparency Team, Sanofi Pasteur, Contact-US@sanofi.com
    Scientific contact
    Trial Transparency Team, Sanofi Pasteur, Contact-US@sanofi.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    Yes
    EMA paediatric investigation plan number(s)
    EMEA-001930-PIP01-16
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    12 Apr 2018
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    10 Oct 2017
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To demonstrate the non-inferiority of the vaccine seroresponse to meningococcal serogroups A, C, Y, and W following the administration of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) compared to that observed following the administration of a single dose of MENVEO® in children aged 2 to 9 years.
    Protection of trial subjects
    Vaccinations were performed by qualified and trained study personnel. Subjects with allergy to any of the vaccine components were not vaccinated. After vaccination, subjects were also kept under clinical observation for 30 minutes to ensure their safety. Appropriate medical equipment was also available on site in case of any immediate allergic reactions.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    17 Feb 2017
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United States: 1000
    Worldwide total number of subjects
    1000
    EEA total number of subjects
    0
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    1000
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Study subjects were enrolled in 36 centers in the Unites States (US) and Puerto Rico from 17 February 2017 to 30 March 2017.

    Pre-assignment
    Screening details
    A total of 1000 subjects who met all of the inclusion criteria and none of the exclusion criteria were enrolled and randomized in the study.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Carer, Assessor

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Group 1: MenACYW Conjugate Vaccine
    Arm description
    Healthy, meningococcal-vaccine naïve subjects aged 2 to 9 years received a single dose of MenACYW conjugate vaccine.
    Arm type
    Experimental

    Investigational medicinal product name
    MenACYW conjugate vaccine: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    0.5 mL, intramuscular, single dose on Day 0.

    Arm title
    Group 2: MENVEO® Vaccine
    Arm description
    Healthy, meningococcal-vaccine naïve subjects aged 2 to 9 years received a single dose of MENVEO® vaccine.
    Arm type
    Active comparator

    Investigational medicinal product name
    MENVEO®: Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder and solution for solution for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    0.5 mL, intramuscular, single dose on Day 0.

    Number of subjects in period 1
    Group 1: MenACYW Conjugate Vaccine Group 2: MENVEO® Vaccine
    Started
    499
    501
    Safety analysis set
    498
    494
    Completed
    487
    487
    Not completed
    12
    14
         Protocol deviation
             3
             5
         Consent withdrawn by subject
             3
             6
         Lost to follow-up
             6
             3

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Group 1: MenACYW Conjugate Vaccine
    Reporting group description
    Healthy, meningococcal-vaccine naïve subjects aged 2 to 9 years received a single dose of MenACYW conjugate vaccine.

    Reporting group title
    Group 2: MENVEO® Vaccine
    Reporting group description
    Healthy, meningococcal-vaccine naïve subjects aged 2 to 9 years received a single dose of MENVEO® vaccine.

    Reporting group values
    Group 1: MenACYW Conjugate Vaccine Group 2: MENVEO® Vaccine Total
    Number of subjects
    499 501 1000
    Age categorical
    Units: Subjects
        In utero
    0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0
        Newborns (0-27 days)
    0 0 0
        Infants and toddlers (28 days-23 months)
    0 0 0
        Children (2-11 years)
    499 501 1000
        Adolescents (12-17 years)
    0 0 0
        Adults (18-64 years)
    0 0 0
        From 65-84 years
    0 0 0
        85 years and over
    0 0 0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    6.0 ± 2.33 6.0 ± 2.36 -
    Gender categorical
    Units: Subjects
        Female
    245 236 481
        Male
    254 265 519
    Region of Enrollment
    Units: Subjects
        United States
    499 501 1000

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Group 1: MenACYW Conjugate Vaccine
    Reporting group description
    Healthy, meningococcal-vaccine naïve subjects aged 2 to 9 years received a single dose of MenACYW conjugate vaccine.

    Reporting group title
    Group 2: MENVEO® Vaccine
    Reporting group description
    Healthy, meningococcal-vaccine naïve subjects aged 2 to 9 years received a single dose of MENVEO® vaccine.

    Primary: Percentages of Subjects Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or MENVEO® Vaccine

    Close Top of page
    End point title
    Percentages of Subjects Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or MENVEO® Vaccine
    End point description
    Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers >=1:16 for subjects with pre-vaccination hSBA titers <1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for subjects with pre-vaccination hSBA titers >=1:8. Analysis was performed on Per-Protocol Analysis Set (PPAS) defined for accessing the ACYW immune response data for all subjects who received at least one dose of study vaccine and had a valid post-vaccination serology result. The subjects who presented pre-defined protocol deviations were excluded from per-protocol analysis set. Here 'n' signifies number of subjects with available data for specified category.
    End point type
    Primary
    End point timeframe
    Day 30 (post-vaccination)
    End point values
    Group 1: MenACYW Conjugate Vaccine Group 2: MENVEO® Vaccine
    Number of subjects analysed
    458
    460
    Units: percentage of subjects
    number (confidence interval 95%)
        Serogroup A (n=455,458)
    55.4 (50.7 to 60.0)
    47.8 (43.2 to 52.5)
        Serogroup C (n=458,458)
    95.2 (92.8 to 97.0)
    47.8 (43.2 to 52.5)
        Serogroup Y (n=458,459)
    91.5 (88.5 to 93.9)
    79.3 (75.3 to 82.9)
        Serogroup W (n=458,459)
    78.8 (74.8 to 82.5)
    64.1 (59.5 to 68.4)
    Statistical analysis title
    Serogroup A
    Statistical analysis description
    Actual number of subjects analyzed = 913
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    918
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority [1]
    Method
    Parameter type
    Percentage Difference
    Point estimate
    7.6
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    1.1
         upper limit
    14
    Notes
    [1] - 95% confidence interval (CI) of the difference was calculated from the Wilson Score Method without continuity correction. Non-inferiority was demonstrated if the lower limit of the 2-sided 95% CI of the difference between the 2 percentages was >-10%.
    Statistical analysis title
    Serogroup C
    Statistical analysis description
    Actual number of subjects analyzed = 916
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    918
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority [2]
    Method
    Parameter type
    Percentage Difference
    Point estimate
    47.4
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    42.2
         upper limit
    52.2
    Notes
    [2] - 95% CI of the difference was calculated from the Wilson Score Method without continuity correction. Non-inferiority was demonstrated if the lower limit of the 2-sided 95% CI of the difference between the 2 percentages was >-10%.
    Statistical analysis title
    Serogroup Y
    Statistical analysis description
    Actual number of subjects analyzed = 917
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    918
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority [3]
    Method
    Parameter type
    Percentage Difference
    Point estimate
    12.2
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    7.7
         upper limit
    16.7
    Notes
    [3] - 95% CI of the difference was calculated from the Wilson Score Method without continuity correction. Non-inferiority was demonstrated if the lower limit of the 2-sided 95% CI of the difference between the 2 percentages was >-10%.
    Statistical analysis title
    Serogroup W
    Statistical analysis description
    Actual number of subjects analyzed = 917
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    918
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority [4]
    Method
    Parameter type
    Percentage Difference
    Point estimate
    14.8
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    8.9
         upper limit
    20.5
    Notes
    [4] - 95% CI of the difference was calculated from the Wilson Score Method without continuity correction. Non-inferiority was demonstrated if the lower limit of the 2-sided 95% CI of the difference between the 2 percentages was >-10%.

    Secondary: Geometric Mean Titers (GMTs) of Meningococcal Serogroups A, C, Y, and W Antibodies Following Vaccination With Either MenACYW Conjugate Vaccine or MENVEO® Vaccine in Children 2 to 9 Years of Age

    Close Top of page
    End point title
    Geometric Mean Titers (GMTs) of Meningococcal Serogroups A, C, Y, and W Antibodies Following Vaccination With Either MenACYW Conjugate Vaccine or MENVEO® Vaccine in Children 2 to 9 Years of Age
    End point description
    Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. Analysis was performed on PPAS. Here 'n' signifies number of subjects with available data for specified category.
    End point type
    Secondary
    End point timeframe
    Day 30 (post-vaccination)
    End point values
    Group 1: MenACYW Conjugate Vaccine Group 2: MENVEO® Vaccine
    Number of subjects analysed
    458
    460
    Units: titers
    geometric mean (confidence interval 95%)
        Serogroup A (n=456,458)
    24.8 (21.9 to 27.9)
    22.6 (19.7 to 26.0)
        Serogroup C (n=458,459)
    238 (209 to 270)
    17.0 (14.3 to 20.2)
        Serogroup Y (n=458,459)
    68.8 (61.3 to 77.3)
    43.5 (37.7 to 50.4)
        Serogroup W (n=458,459)
    37.5 (33.7 to 41.8)
    26.2 (23.0 to 29.9)
    Statistical analysis title
    Serogroup A
    Statistical analysis description
    Actual number of subjects analyzed = 914
    Comparison groups
    Group 2: MENVEO® Vaccine v Group 1: MenACYW Conjugate Vaccine
    Number of subjects included in analysis
    918
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    GMT Ratio
    Point estimate
    1.09
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.91
         upper limit
    1.32
    Statistical analysis title
    Serogroup C
    Statistical analysis description
    Actual number of subjects analyzed = 917
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    918
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    GMT Ratio
    Point estimate
    14
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    11.3
         upper limit
    17.3
    Statistical analysis title
    Serogroup Y
    Statistical analysis description
    Actual number of subjects analyzed = 917
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    918
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    GMT Ratio
    Point estimate
    1.58
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    1.31
         upper limit
    1.9
    Statistical analysis title
    Serogroup W
    Statistical analysis description
    Actual number of subjects analyzed = 917
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    918
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    GMT Ratio
    Point estimate
    1.43
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    1.21
         upper limit
    1.69

    Secondary: GMTs of Meningococcal Serogroups A, C, Y, and W Antibodies Following Vaccination With Either MenACYW Conjugate Vaccine or MENVEO® Vaccine in Children 2 to 5 Years of Age

    Close Top of page
    End point title
    GMTs of Meningococcal Serogroups A, C, Y, and W Antibodies Following Vaccination With Either MenACYW Conjugate Vaccine or MENVEO® Vaccine in Children 2 to 5 Years of Age
    End point description
    Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. Analysis was performed on PPAS. Here 'Number of subjects analysed' signifies number of subjects in the PPAS aged 2-5 years, and 'n' signifies number of subjects with available data for specified category.
    End point type
    Secondary
    End point timeframe
    Day 30 (post-vaccination)
    End point values
    Group 1: MenACYW Conjugate Vaccine Group 2: MENVEO® Vaccine
    Number of subjects analysed
    229
    223
    Units: titers
    geometric mean (confidence interval 95%)
        Serogroup A (n=228,221)
    21.6 (18.2 to 25.5)
    18.9 (15.5 to 23.0)
        Serogroup C (n=229,223)
    208 (175 to 246)
    11.9 (9.79 to 14.6)
        Serogroup Y (n=229,222)
    49.8 (43.0 to 57.6)
    36.1 (29.2 to 44.7)
        Serogroup W (n=229,222)
    28.8 (24.6 to 33.7)
    20.1 (16.7 to 24.2)
    Statistical analysis title
    Serogroup A
    Statistical analysis description
    Actual number of subjects analyzed = 449
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    452
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    GMT Ratio
    Point estimate
    1.14
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.883
         upper limit
    1.47
    Statistical analysis title
    Serogroup C
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    452
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    GMT Ratio
    Point estimate
    17.4
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    13.4
         upper limit
    22.6
    Statistical analysis title
    Serogroup Y
    Statistical analysis description
    Actual number of subjects analyzed = 451
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    452
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    GMT Ratio
    Point estimate
    1.38
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    1.07
         upper limit
    1.78
    Statistical analysis title
    Serogroup W
    Statistical analysis description
    Actual number of subjects analyzed = 451
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    452
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    GMT Ratio
    Point estimate
    1.43
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    1.12
         upper limit
    1.83

    Secondary: GMTs of Meningococcal Serogroups A, C, Y, and W Antibodies Following Vaccination With Either MenACYW Conjugate Vaccine or MENVEO® Vaccine in Children 6 to 9 Years of Age

    Close Top of page
    End point title
    GMTs of Meningococcal Serogroups A, C, Y, and W Antibodies Following Vaccination With Either MenACYW Conjugate Vaccine or MENVEO® Vaccine in Children 6 to 9 Years of Age
    End point description
    Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. Analysis was performed on PPAS. Here 'Number of subjects analysed' signifies number of subjects in the PPAS aged 6-9 years, and 'n' signifies number of subjects with available data for specified category.
    End point type
    Secondary
    End point timeframe
    Day 30 (post-vaccination)
    End point values
    Group 1: MenACYW Conjugate Vaccine Group 2: MENVEO® Vaccine
    Number of subjects analysed
    229
    237
    Units: titers
    geometric mean (confidence interval 95%)
        Serogroup A (n=228,237)
    28.4 (23.9 to 33.8)
    26.8 (22.0 to 32.6)
        Serogroup C (n=229,236)
    272 (224 to 330)
    23.7 (18.2 to 31.0)
        Serogroup Y (n=229,237)
    95.1 (80.2 to 113)
    51.8 (42.5 to 63.2)
        Serogroup W (n=229,237)
    48.9 (42.5 to 56.3)
    33.6 (28.2 to 40.1)
    Statistical analysis title
    Serogroup A
    Statistical analysis description
    Actual number of subjects analyzed = 465
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    466
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    GMT Ratio
    Point estimate
    1.06
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    0.816
         upper limit
    1.38
    Statistical analysis title
    Serogroup C
    Statistical analysis description
    Actual number of subjects analyzed = 465
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    466
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    GMT Ratio
    Point estimate
    11.5
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    8.24
         upper limit
    16
    Statistical analysis title
    Serogroup Y
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    466
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    GMT Ratio
    Point estimate
    1.84
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    1.41
         upper limit
    2.38
    Statistical analysis title
    Serogroup W
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    466
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    GMT Ratio
    Point estimate
    1.45
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    1.16
         upper limit
    1.82

    Secondary: Percentages of Subjects Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or MENVEO® Vaccine in Children 2 to 5 Years of Age

    Close Top of page
    End point title
    Percentages of Subjects Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or MENVEO® Vaccine in Children 2 to 5 Years of Age
    End point description
    Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers >=1:16 for subjects with pre-vaccination hSBA titers <1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for subjects with pre-vaccination hSBA titers >=1:8. Analysis was performed on PPAS. Here 'Number of subjects analysed' signifies number of subjects in the PPAS aged 2-5 years, and 'n' signifies number of subjects with available data for specified category.
    End point type
    Secondary
    End point timeframe
    Day 30 (post-vaccination)
    End point values
    Group 1: MenACYW Conjugate Vaccine Group 2: MENVEO® Vaccine
    Number of subjects analysed
    229
    223
    Units: percentage of subjects
    number (confidence interval 95%)
        Serogroup A (n=227,221)
    52.4 (45.7 to 59.1)
    44.8 (38.1 to 51.6)
        Serogroup C (n=229,222)
    94.3 (90.5 to 96.9)
    43.2 (36.6 to 50.0)
        Serogroup Y (n=229,222)
    88.2 (83.3 to 92.1)
    77.0 (70.9 to 82.4)
        Serogroup W (n=229,222)
    73.8 (67.6 to 79.4)
    61.3 (54.5 to 67.7)
    Statistical analysis title
    Serogroup A
    Statistical analysis description
    Actual number of subjects analyzed = 448
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    452
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Percentage Difference
    Point estimate
    7.6
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.6
         upper limit
    16.7
    Statistical analysis title
    Serogroup C
    Statistical analysis description
    Actual number of subjects analyzed = 451
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    452
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Percentage Difference
    Point estimate
    51.1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    43.5
         upper limit
    57.8
    Statistical analysis title
    Serogroup Y
    Statistical analysis description
    Actual number of subjects analyzed = 451
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    452
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Percentage Difference
    Point estimate
    11.2
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    4.2
         upper limit
    18.1
    Statistical analysis title
    Serogroup W
    Statistical analysis description
    Actual number of subjects analyzed = 451
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    452
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Percentage Difference
    Point estimate
    12.5
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    3.9
         upper limit
    20.9

    Secondary: Percentages of Subjects Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or MENVEO® Vaccine in Children 6 to 9 Years of Age

    Close Top of page
    End point title
    Percentages of Subjects Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or MENVEO® Vaccine in Children 6 to 9 Years of Age
    End point description
    Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers >=1:16 for subjects with pre-vaccination hSBA titers <1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for subjects with pre-vaccination hSBA titers >=1:8. Analysis was performed on PPAS. Here 'Number of subjects analysed' signifies number of subjects in the PPAS aged 6-9 years, and 'n' signifies number of subjects with available data for specified category.
    End point type
    Secondary
    End point timeframe
    Day 30 (post-vaccination)
    End point values
    Group 1: MenACYW Conjugate Vaccine Group 2: MENVEO® Vaccine
    Number of subjects analysed
    229
    237
    Units: percentage of subjects
    number (confidence interval 95%)
        Serogroup A (n=228,237)
    58.3 (51.6 to 64.8)
    50.6 (44.1 to 57.2)
        Serogroup C (n=229,236)
    96.1 (92.7 to 98.2)
    52.1 (45.5 to 58.6)
        Serogroup Y (n=229,237)
    94.8 (91.0 to 97.3)
    81.4 (75.9 to 86.2)
        Serogroup W (n=229,237)
    83.8 (78.4 to 88.4)
    66.7 (60.3 to 72.6)
    Statistical analysis title
    Serogroup A
    Statistical analysis description
    Actual number of subjects analyzed = 465
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    466
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Percentage Difference
    Point estimate
    7.7
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -1.3
         upper limit
    16.6
    Statistical analysis title
    Serogroup C
    Statistical analysis description
    Actual number of subjects analyzed = 465
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    466
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Percentage Difference
    Point estimate
    44
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    36.8
         upper limit
    50.6
    Statistical analysis title
    Serogroup Y
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    466
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Percentage Difference
    Point estimate
    13.3
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    7.6
         upper limit
    19.2
    Statistical analysis title
    Serogroup W
    Comparison groups
    Group 1: MenACYW Conjugate Vaccine v Group 2: MENVEO® Vaccine
    Number of subjects included in analysis
    466
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    Parameter type
    Percentage Difference
    Point estimate
    17.2
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    9.4
         upper limit
    24.7

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Adverse event (AE) data were collected from Day 0 up to Day 30 post-vaccination. Solicited Reaction (SR) data were collected from Day 0 up to Day 7 post-vaccination.
    Adverse event reporting additional description
    A SR was an AE that was prelisted (i.e.,solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the eCRF (i.e.,solicited) in terms of symptom and/or onset post-vaccination. Safety analysis set.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    19.0
    Reporting groups
    Reporting group title
    Group 2: MENVEO® Vaccine
    Reporting group description
    Healthy, meningococcal-vaccine naïve subjects aged 2 to 9 years received a single dose of MENVEO® vaccine.

    Reporting group title
    Group 1: MenACYW Conjugate Vaccine
    Reporting group description
    Healthy, meningococcal-vaccine naïve subjects aged 2 to 9 years received a single dose of MenACYW conjugate vaccine.

    Serious adverse events
    Group 2: MENVEO® Vaccine Group 1: MenACYW Conjugate Vaccine
    Total subjects affected by serious adverse events
         subjects affected / exposed
    3 / 494 (0.61%)
    7 / 498 (1.41%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    Vascular disorders
    Circulatory Collapse
         subjects affected / exposed
    0 / 494 (0.00%)
    1 / 498 (0.20%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Adenoidal Hypertrophy
         subjects affected / exposed
    1 / 494 (0.20%)
    1 / 498 (0.20%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Asthma
         subjects affected / exposed
    1 / 494 (0.20%)
    1 / 498 (0.20%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Status Asthmaticus
         subjects affected / exposed
    0 / 494 (0.00%)
    1 / 498 (0.20%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Tonsillar Hypertrophy
         subjects affected / exposed
    1 / 494 (0.20%)
    1 / 498 (0.20%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Wheezing
         subjects affected / exposed
    0 / 494 (0.00%)
    1 / 498 (0.20%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    Partial Seizures
         subjects affected / exposed
    1 / 494 (0.20%)
    0 / 498 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Tethered Cord Syndrome
         subjects affected / exposed
    0 / 494 (0.00%)
    1 / 498 (0.20%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Osteomyelitis
         subjects affected / exposed
    0 / 494 (0.00%)
    1 / 498 (0.20%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Group 2: MENVEO® Vaccine Group 1: MenACYW Conjugate Vaccine
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    335 / 494 (67.81%)
    304 / 498 (61.04%)
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    30 / 494 (6.07%)
    34 / 498 (6.83%)
         occurrences all number
    33
    36
    Nervous system disorders
    Headache
         subjects affected / exposed
    60 / 494 (12.15%)
    64 / 498 (12.85%)
         occurrences all number
    63
    65
    General disorders and administration site conditions
    Injection Site Erythema
         subjects affected / exposed
    153 / 494 (30.97%)
    110 / 498 (22.09%)
         occurrences all number
    154
    110
    Injection Site Swelling
         subjects affected / exposed
    104 / 494 (21.05%)
    67 / 498 (13.45%)
         occurrences all number
    105
    67
    Injection Site Pain
         subjects affected / exposed
    206 / 494 (41.70%)
    188 / 498 (37.75%)
         occurrences all number
    206
    188
    Malaise
         subjects affected / exposed
    99 / 494 (20.04%)
    103 / 498 (20.68%)
         occurrences all number
    99
    103
    Pyrexia
         subjects affected / exposed
    27 / 494 (5.47%)
    20 / 498 (4.02%)
         occurrences all number
    27
    21
    Musculoskeletal and connective tissue disorders
    Myalgia
         subjects affected / exposed
    112 / 494 (22.67%)
    99 / 498 (19.88%)
         occurrences all number
    112
    99
    Infections and infestations
    Pharyngitis
         subjects affected / exposed
    25 / 494 (5.06%)
    24 / 498 (4.82%)
         occurrences all number
    34
    31
    Pharyngitis Streptococcal
         subjects affected / exposed
    34 / 494 (6.88%)
    18 / 498 (3.61%)
         occurrences all number
    38
    23
    Upper Respiratory Tract Infection
         subjects affected / exposed
    25 / 494 (5.06%)
    20 / 498 (4.02%)
         occurrences all number
    30
    24

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    23 Aug 2017
    Following amendments were made- To accurately document the countries where the study was being conducted, Puerto Rico was added to different sections of the protocol as applicable. - Coordinating investigator information was added.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2019 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA